According to a new research report titled ‘Chronic Obstructive Pulmonary Disease Treatment Market (By Drug Class: Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, Others; By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026’ by Acumen Research and Consulting.
LOS ANGELES, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Global chronic obstructive pulmonary disease market size is anticipated to value around USD 24.3 billion by 2026. The market is foreseeable to display a CAGR of 4.9% during the coming years.
Free Download Sample Report Pages For Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1145
Various market players have gotten endorsements from the Food and Drug Administration (FDA), the European Commission, and other administrative experts in the previous couple of years. These players have propelled new products, for example, triple treatment drugs and different blends in the market, empowering them to increase noteworthy market share of the overall industry. In December 2018, AstraZeneca got endorsement from the European Commission (EC) for Bevespi Aerosphere in a pressurized metered-portion inhaler (pMDI) demonstrated as an upkeep double bronchodilator treatment in grown-up patients with COPD. This endorsement empowered the organization to add its innovatively propelled item to the current item offering for patients in Europe. In December 2018, Teva Pharmaceutical Industries Ltd. gotten the U.S. Sustenance and Drug Administration (FDA) endorsement for ProAir Digihaler inhaler powder, which is a digital inhaler with inherent sensors suggested to a sidekick versatile application. This endorsement helped the organization to fortify its development abilities in respiratory consideration, in this manner accomplishing huge development in the market.
The global chronic obstructive pulmonary disease treatment market is segmented into drug class, distribution channel and region. On the basis drug class, the global chronic obstructive pulmonary disease treatment market is segmented into Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, and Others. On the basis distribution channel, the global chronic obstructive pulmonary disease treatment market is segmented into Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies. On the basis of region the global chronic obstructive pulmonary disease treatment market is bifurcated into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific.
View Detail Information With Complete TOC@ https://www.acumenresearchandconsulting.com/chronic-obstructive-pulmonary-disease-treatment-market
Based on distribution channel, the market has been arranged into retail drug stores, emergency clinic drug stores, and online drug stores. The retail drug stores segment is required to grow at the quickest CAGR because of surge in the number of patients leaning toward retail drug stores. The online drug stores section is probably going to be driven by ascend in mindfulness about these drug stores among the overall public.
On the basis of drug class, the worldwide chronic obstructive pulmonary disease treatment market has been sectioned into bronchodilators, combination, phosphodiesterase type 4 inhibitors, corticosteroids, mucokinetics, and others. The combination segment has been segmented into long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), and others. The bronchodilators segment has been bifurcated into short acting beta agonist (SABA), long acting beta agonist (LABA), and long acting muscarinic rival (LAMA). The combination segment is anticipated to represent major share of the market by 2026 because of increment in number of doctors recommending combination treatment and increase in the number of medications accessible for COPD treatment. The bronchodilators segment is foreseen to develop at a steady pace attributable to increment in the appropriation of long acting muscarinic rival (LAMA) drugs.
Based on the region, the worldwide chronic obstructive pulmonary disease (COPD) treatment market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. North America represented the biggest revenue share of the worldwide market in 2018. Presence of built up pharmaceutical organizations, increment in adoption of new drugs propelled in the market, and concentrate on dispatch of new products through R&D are foreseen to drive the market in the area amid the estimate time frame.
Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases
Explore Our Market Blog@ https://www.acumenresearchandconsulting.com/blogs
The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by increment in R&D spending and introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. gotten approval from the European Commission for extended use for once-daily TrelegyEllipta, first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.
Increase in commonness of COPD, high environmental contamination, increment in the geriatric populace, and development of the pharmaceutical business are foreseen to fuel the development of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences expressed that COPD is the third driving reason for death in India.
The main business working in the global chronic obstructive pulmonary disease market are Orion Corporation, AstraZeneca, Mylan N.V., Boehringer Ingelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A.
INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1145
The report is readily available and can be dispatched immediately after payment confirmation.
Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/1145
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
For Latest Update Follow Us:
https://www.facebook.com/acumenresearchandconsulting
https://www.linkedin.com/company/acumen-research-and-consulting/
Browse More Press Releases: http://www.amecoresearch.com/